Click to read more about LabGenius' recent Innovate UK grant win
Click to read more about LabGenius' recent Innovate UK grant win
We’re driven by
our mission.
Looking to the future, the next wave of major scientific breakthroughs will be unlocked by technology platforms that are capable of combining the very best of human ingenuity and machine intelligence.
Armed with this knowledge, our mission is to accelerate the discovery of next-generation therapeutic antibodies. To do this, we’re pioneering the development of a smart robotic platform (EVA™) that’s capable of designing, conducting and — critically — learning from its own experiments.
We believe this approach will radically improve the drug discovery process, making the generation of advanced antibody therapeutics faster.
Platform technology.
The discovery of protein therapeutics has thus far been highly artisanal, relying heavily on humans for both experimental design and execution. This is why we’ve seen diminishing returns for decades, as we’re just not cognitively capable of fully grasping the complexities of biological systems.
But that’s where EVA™ comes in. By combining robotic automation, synthetic biology, and advanced machine learning, we run the full design-build-test-learn cycle to help direct our search for novel therapeutic antibodies.
Through the development of machine learning (ML) models that describe sequence to function relationships, we’re able to explore protein fitness landscapes and improve multiple drug properties simultaneously.
Read more on our Medium Publication:
Why it’s taken so long to disrupt drug discovery
How LabGenius is revolutionizing drug discovery with machine learning
Drug discovery the LabGenius way: a protein scientist gives us the tour
Platform applications.
We are initially deploying EVA™ to the rapid discovery and optimization of novel therapeutic antibodies, for the treatment of cancer and inflammatory diseases.
So far, we’ve used our platform to co-optimize mono- and multi-specific single domain antibodies for both biophysical and functional properties, including stability, potency and cell selectivity.
In parallel with partnered projects, the development of our internal pipeline is well underway, focusing on the discovery and optimization of immunotherapeutics. Learn more about our immune cell engager lead optimization capability by watching the video below.
Our investors.
Partnerships.
Partnering with LabGenius provides access to our
ML-driven protein engineering platform, EVA™. We are looking for partnerships for the discovery and optimization of antibody therapeutics.
If you have a complex protein engineering problem that needs solving, please get in touch.
Latest news.
News
Our team.
LabGenius’ highly multidisciplinary team brings together the best minds from the fields of computer science, robotic automation and synthetic biology.
We work by
our values.
Commitment to our company values has been core to LabGenius’ successes so far. They define the principles by which we work with one another, and our stakeholders, to drive the company forward. We’re incredibly proud of the culture we have cultivated, and our values continue to hold us accountable.
Feeling inspired?
UK Headquarters
G04 Cocoa Studios
The Biscuit Factory
100 Drummond Road
London
SE16 4DG
